Clinical Trial Search

Phase 3 N=765 A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia

Schizophrenia

Primary: Time From Baseline to the First Symptom Relapse During the Double-blind Phase — 92; 224 Days — p=0.0010

Forest Laboratories Results Jul 2018 4.5% serious AE View details

Phase 3 N=208 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)

Chronic Inflammatory Demyelinating Polyneuropathy · Polyradiculoneuropathy

Primary: Percentage (%) of Subjects With CIDP Relapse or Are Withdrawn for Any Other Reason During the Subcutaneous (SC) Treatment Period — 32.8; 38.6; 63.2 percentage of…

CSL Behring Results Jul 2018 4.3% serious AE View details

Phase 3 N=140 MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma

Lymphoma, Non Hodgkin

Primary: Percentage of Participants With Administration-Associated Reactions (AARs) — 34.5; 52.3; 48.6; 0 percentage of participants

Hoffmann-La Roche Results Jul 2018 30.0% serious AE View details

Phase 3 N=53 Urea Breath Test (UBT) With Breath Hp System /BreathID Hp Lab System Pediatrics

Helicobacter Pylori Infection

Primary: Number of Participants With Reported Adverse Events — 1 Participants

Meridian Bioscience, Inc. Results Jul 2018 0.0% serious AE View details

Phase 3 N=1,300 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults

Infections, Meningococcal

Primary: Anti-Meningitis Antibody Titers by Serum Bactericidal Assay Using Rabbit Complement (rSBA) — 5517.1; 5523.5; 4649.6; 4277.3 Titers

GlaxoSmithKline Results Jul 2018 1.8% serious AE View details

Phase 3 N=1,504 Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System

Contraception

Primary: Pregnancy — 5.41; 6.67; 6.43 Pearl Index

Agile Therapeutics Results Jul 2018 1.1% serious AE View details

Phase 3 N=1,736 Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age

Measles; Mumps; Rubella · Measles-Mumps-Rubella Vaccine

Primary: Number of Subjects Reporting Fever After MMR (Priorix or M-M-R II/M-M-R VaxPro [Lot 1 or Lot 2]) Vaccination — 47; 17; 205; 95 Participants

GlaxoSmithKline Results Jul 2018 1.9% serious AE View details

Phase 3 N=117 Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen

Hepatitis C Virus Infection

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 85.1; 70.0; 97.9; 91.7 percentage of participants…

Gilead Sciences Results Jul 2018 3.4% serious AE View details

Phase 3 N=60 Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection

Hepatitis B

Primary: Proportion of Participants With Hepatitis B e Antigen (HBeAg) Loss & Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels ≤1,000 International Units (IU) Per…

National Institute of Diabetes and Digestive and… Results Jul 2018 1.7% serious AE View details

Phase 3 N=114 Diazepam Use With Standard Management for Acute Low Back Pain

Low Back Pain

Primary: Change in Functional Impairment as Measured by the Roland Morris Disability Questionnaire — 11; 11 units on a scale

Montefiore Medical Center Results Jul 2018 0.0% serious AE View details

Phase 3 N=1,230 A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Participants Undergoing Hematopoietic Cell Transplants (HCTs) (V212-001)

Herpes Zoster

Primary: Incidence of Confirmed Herpes-Zoster — 32.889; 91.883 Number of cases per 1000 person years

Merck Sharp & Dohme LLC Results Jul 2018 65.6% serious AE View details

Phase 3 N=304 A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting

Bladder Cancer

Primary: Proportion of Patients With Histologically Confirmed Malignancy Where Malignancy is Only Detected With Blue Light Cystoscopy With Cysview and Not White Light Cystoscopy…

Photocure Results Jul 2018 0.3% serious AE View details

Phase 3 N=7 An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects

Epilepsy

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability of Perampanel — 6; 0; 0…

Eisai Co., Ltd. Results Jul 2018 0.0% serious AE View details

Phase 3 N=791 Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

Primary: The Percent of Subjects Meeting Treatment Response Criteria at Week 48 According to a Combined Response Index — 33.5; 34.1; 35.2 Percentage of responders — p==0.899

UCB Pharma Results Jun 2018 17.8% serious AE View details

Phase 3 N=793 Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

Primary: The Percent of Subjects Meeting Treatment Response Criteria at Week 48 According to a Combined Response Index — 34.1; 39.8; 37.5 percentage of participants — p==0.175

UCB Pharma Results Jun 2018 17.4% serious AE View details